Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ME2 | P23368 | 1/20 | 0.60 |
| ▸ | ME1 | P48163 | 1/20 | 0.60 |
| ▸ | ME3 | Q16798 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | AR | P10275 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | GPR183 | P32249 | 3/20 | 0.55 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909561 | 1.00 | KMT2A (0.73) | KMT2AMEN1RAB9APOLBME2 | |
| Piperazine SCHEMBL28235313 | 0.98 | KMT2A (0.71) | KMT2AMEN1RAB9APOLBME2 | |
| Hydrochloric Acid SCHEMBL10853332 | 0.98 | KMT2A (0.71) | KMT2AMEN1RAB9APOLBME2 | |
| Hydrochloric Acid SCHEMBL10853322 | 0.98 | KMT2A (0.71) | KMT2AMEN1RAB9APOLBME2 | |
| SCHEMBL10282873 | 0.94 | MEN1 (0.74) | KMT2AMEN1RAB9APOLBME2 | |
| SCHEMBL10720639 | 0.91 | MEN1 (0.60) | KMT2AMEN1RAB9APOLBME2 | |
| SCHEMBL10720634 | 0.91 | MEN1 (0.60) | KMT2AMEN1RAB9APOLBME2 | |
| SCHEMBL4456981 | 0.89 | KMT2A (0.89) | KMT2AMEN1RAB9APOLBME2 | |
| SCHEMBL16599447 | 0.89 | KMT2A (0.89) | KMT2AMEN1RAB9APOLBME2 | |
| SCHEMBL16599448 | 0.89 | KMT2A (0.89) | KMT2AMEN1RAB9APOLBME2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61010593-A | — | — | None | — | — | JP | disclosed |
| CN-117820287-A | Magnolol derivative, and preparation method and application thereof | 中国药科大学 | 2024-04-05 | — | — | CN | disclosed |
| EP-3143036-B1 | PAR-1 BASED THERAPEUTIC CONJUGATES AND USES THEREOF | TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD (IL) | 2023-08-02 | — | — | EP | disclosed |
| CN-108440440-B | Naphthalene ring-containing 1,2, 4-oxadiazole-cinnamoyl piperazine compound and preparation method and application thereof | 贵州医科大学 | 2021-07-13 | — | — | CN | disclosed |
| US-10028999-B2 | PAR-1 based therapeutic conjugates and uses thereof | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2018-07-24 | — | — | US | disclosed |
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3143036-A1 | PAR-1 BASED THERAPEUTIC CONJUGATES AND USES THEREOF | Tel Hashomer Medical Research Infrastructure and Services Ltd. (IL) | 2017-03-22 | — | — | EP | disclosed |
| US-20170072014-A1 | PAR-1 BASED THERAPEUTIC CONJUGATES AND USES THEREOF | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2017-03-16 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
| JP-S6110593-A | THIAZINOBENZIMIDAZOLE DERIVATIVE | SS PHARMACEUT CO LTD | 1986-01-18 | — | — | JP | disclosed |
| US-4560755-A | VASODILATOR, HYPOTENSOR | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-12-24 | — | — | US | disclosed |
| US-4525589-A | Isoquinolinesulfonyl derivatives | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-06-25 | — | — | US | disclosed |
| EP-0066919-B1 | 4-ALKYL-THIOPHENYL-ETHANOLAMINES, HAVING AN ACTIVITY ON THE CEREBRAL CIRCULATION, THE BLOOD PLATELET-AGGREGATION AND THE LIPEMIA | MAGGIONI FARMACEUTICI S.p.A. (IT) | 1985-03-20 | — | — | EP | disclosed |
| EP-0061673-B1 | ISOQUINOLINESULFONYL DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-10-24 | — | — | EP | disclosed |
| US-4456757-A | MUSCLE RELAXANTS, VASODILATORS, HYPOTENSIVE AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1984-06-26 | — | — | US | disclosed |
| EP-0066919-A1 | 4-Alkyl-thiophenyl-ethanolamines, having an activity on the cerebral circulation, the blood platelet-aggregation and the lipemia | MAGGIONI FARMACEUTICI S.p.A. (IT) | 1982-12-15 | — | — | EP | disclosed |
| EP-0061673-A1 | Isoquinolinesulfonyl derivatives and process for the preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-10-06 | — | — | EP | disclosed |
| US-4189484-A | Antihypertensive quinazoline derivatives | MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) | 1980-02-19 | — | — | US | disclosed |
| US-4001223-A | CEREBRAL VASODILATORS | IDEMITSU KOSAN CO., LTD. (JA) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214951-A1 | EBI2 MODULATORS | BIRC2, HAVCR2, MAVS | KMT2A 1057/4885MEN1 2201/4885RAB9A 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.